PON1 and PON3 in Alzheimer's Disease: Similar Functions but Different Roles

Overview

Journal Antioxidants (Basel)

Date 2024 Oct 26

PMID 39456469

Authors

Alessandro Trentini

Valentina Rosta

Raffaella Riccetti

Gianmarco Mola

Riccardo Galletti

Marco Pinotti

Vincenza Senia

Giovanni Zuliani

Carlo Cervellati

Affiliations

Soon will be listed here.

Abstract

Paraoxonase 1 (PON1) and Paraoxonase 3 (PON3) are enzymes located on the surface of high-density lipoprotein (HDL) and share similar antioxidant properties, possibly modulated by other proteins such as Myeloperoxidase (MPO), which drives the shift from functional to dysfunctional HDL. PON1 has been extensively studied in relation to Alzheimer's Disease (AD), but the role of PON3 remains unknown. To fill this knowledge gap, the study analyzed PON3 protein levels and PON1-arylesterase activity in 99 AD patients, 100 patients with mild cognitive impairment (MCI), and 79 cognitively normal controls. The results showed that serum PON3 levels remained unchanged across all groups. In contrast, serum arylesterase activity was significantly reduced in both AD and MCI patients compared to controls ( < 0.001 for both comparisons). Surprisingly, there was no correlation between arylesterase activity and MPO protein concentration or activity. However, PON3 was found to have a significant positive correlation with both MPO concentration (r = 0.507, < 0.0001) and MPO activity (r = 0.264, < 0.01). In conclusion, we demonstrated for the first time that PON1 and PON3 have distinct relationships with AD, with only PON1 showing a decrease in activity in this disease, while PON3 levels remained unchanged. Another noteworthy finding was the selective correlation between PON3 and MPO, which may suggest a preferential physical association of PON3 with dysfunctional HDL.

References

Cervellati C, Romani A, Bergamini C, Bosi C, Sanz J, Passaro A . PON-1 and ferroxidase activities in older patients with mild cognitive impairment, late onset Alzheimer's disease or vascular dementia. Clin Chem Lab Med. 2014; 53(7):1049-56. DOI: 10.1515/cclm-2014-0803. View

Trentini A, Rosta V, Spadaro S, Bellini T, Rizzo P, Vieceli Dalla Sega F . Development, optimization and validation of an absolute specific assay for active myeloperoxidase (MPO) and its application in a clinical context: role of MPO specific activity in coronary artery disease. Clin Chem Lab Med. 2020; 58(10):1749-1758. DOI: 10.1515/cclm-2019-0817. View

Marsillach J, Mackness B, Mackness M, Riu F, Beltran R, Joven J . Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic Biol Med. 2008; 45(2):146-57. DOI: 10.1016/j.freeradbiomed.2008.03.023. View

Castellazzi M, Trentini A, Romani A, Valacchi G, Bellini T, Bonaccorsi G . Decreased arylesterase activity of paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases. Int J Biochem Cell Biol. 2016; 81(Pt B):356-363. DOI: 10.1016/j.biocel.2016.06.008. View

James R . A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin Chem Lab Med. 2006; 44(9):1052-9. DOI: 10.1515/CCLM.2006.207. View

Mostafalou S, Abdollahi M . The link of organophosphorus pesticides with neurodegenerative and neurodevelopmental diseases based on evidence and mechanisms. Toxicology. 2018; 409:44-52. DOI: 10.1016/j.tox.2018.07.014. View

Cervellati C, Valacchi G, Tisato V, Zuliani G, Marsillach J . Evaluating the link between Paraoxonase-1 levels and Alzheimer's disease development. Minerva Med. 2018; 110(3):238-250. PMC: 7451062. DOI: 10.23736/S0026-4806.18.05875-5. View

Draganov D, Stetson P, Watson C, Billecke S, La Du B . Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem. 2000; 275(43):33435-42. DOI: 10.1074/jbc.M004543200. View

Paragh G, Balla P, Katona E, Seres I, Egerhazi A, Degrell I . Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci. 2002; 252(2):63-7. DOI: 10.1007/s004060200013. View

10.

Reddy S, Wadleigh D, Grijalva V, Ng C, Hama S, Gangopadhyay A . Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol. 2001; 21(4):542-7. DOI: 10.1161/01.atv.21.4.542. View

11.

Nicholls S, Zheng L, Hazen S . Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends Cardiovasc Med. 2005; 15(6):212-9. DOI: 10.1016/j.tcm.2005.06.004. View

12.

Menini T, Gugliucci A . Paraoxonase 1 in neurological disorders. Redox Rep. 2013; 19(2):49-58. PMC: 6837708. DOI: 10.1179/1351000213Y.0000000071. View

13.

Ceron J, Tecles F, Tvarijonaviciute A . Serum paraoxonase 1 (PON1) measurement: an update. BMC Vet Res. 2014; 10:74. PMC: 3985595. DOI: 10.1186/1746-6148-10-74. View

14.

Teiber J, Draganov D, La Du B . Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem Pharmacol. 2003; 66(6):887-96. DOI: 10.1016/s0006-2952(03)00401-5. View

15.

Arevalo-Rodriguez I, Smailagic N, Roque I Figuls M, Ciapponi A, Sanchez-Perez E, Giannakou A . Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2015; (3):CD010783. PMC: 6464748. DOI: 10.1002/14651858.CD010783.pub2. View

16.

Romani A, Trentini A, van der Flier W, Bellini T, Zuliani G, Cervellati C . Arylesterase Activity of Paraoxonase-1 in Serum and Cerebrospinal Fluid of Patients with Alzheimer's Disease and Vascular Dementia. Antioxidants (Basel). 2020; 9(5). PMC: 7278748. DOI: 10.3390/antiox9050456. View

17.

Litvinov D, Mahini H, Garelnabi M . Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci. 2012; 4(11):523-32. PMC: 3503369. DOI: 10.4103/1947-2714.103310. View

18.

Khersonsky O, Tawfik D . Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry. 2005; 44(16):6371-82. DOI: 10.1021/bi047440d. View

19.

Camps J, Marsillach J, Joven J . The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci. 2009; 46(2):83-106. DOI: 10.1080/10408360802610878. View

20.

Wehr H, Bednarska-Makaruk M, Graban A, Lipczynska-Lojkowska W, Rodo M, Bochynska A . Paraoxonase activity and dementia. J Neurol Sci. 2009; 283(1-2):107-8. DOI: 10.1016/j.jns.2009.02.317. View